QTc interval, CYP2D6 and CYP2C9 genotypes and risperidone plasma concentrations

Adrián Llerena, R. Berecz, Pedro Dorado, Alfredo De La Rubis

Research output: Contribution to journalArticle

56 Citations (Scopus)

Abstract

The role of certain drug metabolizing enzymes in cardiotoxicity, such as CYP2D6 for thioridazine, has been suggested. Risperidone has been shown to inhibit the delayed rectifier leading to lengthening of cardiac repolarization. The heart-rate corrected QT (QTc) interval lengthening has been reported in psychiatric patients receiving risperidone under steady-state conditions. CYP2D6 is involved in the metabolism of risperidone to 9-hydroxy (OH)-risperidone. CYP2C9 enzyme is also involved in the metabolism of several psychotropic drugs, although there are no data about its implication in risperidone metabolism. The present study aimed to evaluate the influence of CYP2D6 and CYP2C9 genotypes, and plasma concentrations of risperidone and 9-OH-risperidone on the QTc interval in patients under steady-state conditions. The relevance of CYP2D6 and CYP2C9 genotypes on risperidone metabolism was also analysed. Thirty-five White European psychiatric patients receiving risperidone monotherapy were studied. QTc interval was longer (p <0.05) in subjects with one active CYP2D6 gene compared to those with two. The number of CYP2D6 active genes was related to the dose-corrected plasma concentration of risperidone (p <0.05), the active moiety (risperidone plus 9-OH-risperidone) (p <0.05) and the risperidone/9-OH-risperidone ratio (p <0.05). CYP2C9 genotypes were not related to plasma concentrations of risperidone or 9-OH-risperidone, nor QTc interval. The results suggest that CYP2D6, but not CYP2C9, may be related to QTc lengthening during treatment with risperidone. The effect of the CYP2D6 genotype in risperidone metabolism is also shown.

Original languageEnglish
Pages (from-to)189-193
Number of pages5
JournalJournal of Psychopharmacology
Volume18
Issue number2
DOIs
Publication statusPublished - Jun 2004

Fingerprint

Cytochrome P-450 CYP2D6
Risperidone
Genotype
Cytochrome P-450 CYP2C9
Psychiatry
Thioridazine
Psychotropic Drugs

Keywords

  • 9-hydroxy-risperidone
  • CYP2C9
  • CYP2D6
  • QTc
  • Risperidone

ASJC Scopus subject areas

  • Pharmacology
  • Psychiatry and Mental health
  • Neuroscience(all)

Cite this

QTc interval, CYP2D6 and CYP2C9 genotypes and risperidone plasma concentrations. / Llerena, Adrián; Berecz, R.; Dorado, Pedro; De La Rubis, Alfredo.

In: Journal of Psychopharmacology, Vol. 18, No. 2, 06.2004, p. 189-193.

Research output: Contribution to journalArticle

Llerena, Adrián ; Berecz, R. ; Dorado, Pedro ; De La Rubis, Alfredo. / QTc interval, CYP2D6 and CYP2C9 genotypes and risperidone plasma concentrations. In: Journal of Psychopharmacology. 2004 ; Vol. 18, No. 2. pp. 189-193.
@article{b338ef12b0d94bb18037b9afd7e69842,
title = "QTc interval, CYP2D6 and CYP2C9 genotypes and risperidone plasma concentrations",
abstract = "The role of certain drug metabolizing enzymes in cardiotoxicity, such as CYP2D6 for thioridazine, has been suggested. Risperidone has been shown to inhibit the delayed rectifier leading to lengthening of cardiac repolarization. The heart-rate corrected QT (QTc) interval lengthening has been reported in psychiatric patients receiving risperidone under steady-state conditions. CYP2D6 is involved in the metabolism of risperidone to 9-hydroxy (OH)-risperidone. CYP2C9 enzyme is also involved in the metabolism of several psychotropic drugs, although there are no data about its implication in risperidone metabolism. The present study aimed to evaluate the influence of CYP2D6 and CYP2C9 genotypes, and plasma concentrations of risperidone and 9-OH-risperidone on the QTc interval in patients under steady-state conditions. The relevance of CYP2D6 and CYP2C9 genotypes on risperidone metabolism was also analysed. Thirty-five White European psychiatric patients receiving risperidone monotherapy were studied. QTc interval was longer (p <0.05) in subjects with one active CYP2D6 gene compared to those with two. The number of CYP2D6 active genes was related to the dose-corrected plasma concentration of risperidone (p <0.05), the active moiety (risperidone plus 9-OH-risperidone) (p <0.05) and the risperidone/9-OH-risperidone ratio (p <0.05). CYP2C9 genotypes were not related to plasma concentrations of risperidone or 9-OH-risperidone, nor QTc interval. The results suggest that CYP2D6, but not CYP2C9, may be related to QTc lengthening during treatment with risperidone. The effect of the CYP2D6 genotype in risperidone metabolism is also shown.",
keywords = "9-hydroxy-risperidone, CYP2C9, CYP2D6, QTc, Risperidone",
author = "Adri{\'a}n Llerena and R. Berecz and Pedro Dorado and {De La Rubis}, Alfredo",
year = "2004",
month = "6",
doi = "10.1177/0269881104042618",
language = "English",
volume = "18",
pages = "189--193",
journal = "Journal of Psychopharmacology",
issn = "0269-8811",
publisher = "SAGE Publications Ltd",
number = "2",

}

TY - JOUR

T1 - QTc interval, CYP2D6 and CYP2C9 genotypes and risperidone plasma concentrations

AU - Llerena, Adrián

AU - Berecz, R.

AU - Dorado, Pedro

AU - De La Rubis, Alfredo

PY - 2004/6

Y1 - 2004/6

N2 - The role of certain drug metabolizing enzymes in cardiotoxicity, such as CYP2D6 for thioridazine, has been suggested. Risperidone has been shown to inhibit the delayed rectifier leading to lengthening of cardiac repolarization. The heart-rate corrected QT (QTc) interval lengthening has been reported in psychiatric patients receiving risperidone under steady-state conditions. CYP2D6 is involved in the metabolism of risperidone to 9-hydroxy (OH)-risperidone. CYP2C9 enzyme is also involved in the metabolism of several psychotropic drugs, although there are no data about its implication in risperidone metabolism. The present study aimed to evaluate the influence of CYP2D6 and CYP2C9 genotypes, and plasma concentrations of risperidone and 9-OH-risperidone on the QTc interval in patients under steady-state conditions. The relevance of CYP2D6 and CYP2C9 genotypes on risperidone metabolism was also analysed. Thirty-five White European psychiatric patients receiving risperidone monotherapy were studied. QTc interval was longer (p <0.05) in subjects with one active CYP2D6 gene compared to those with two. The number of CYP2D6 active genes was related to the dose-corrected plasma concentration of risperidone (p <0.05), the active moiety (risperidone plus 9-OH-risperidone) (p <0.05) and the risperidone/9-OH-risperidone ratio (p <0.05). CYP2C9 genotypes were not related to plasma concentrations of risperidone or 9-OH-risperidone, nor QTc interval. The results suggest that CYP2D6, but not CYP2C9, may be related to QTc lengthening during treatment with risperidone. The effect of the CYP2D6 genotype in risperidone metabolism is also shown.

AB - The role of certain drug metabolizing enzymes in cardiotoxicity, such as CYP2D6 for thioridazine, has been suggested. Risperidone has been shown to inhibit the delayed rectifier leading to lengthening of cardiac repolarization. The heart-rate corrected QT (QTc) interval lengthening has been reported in psychiatric patients receiving risperidone under steady-state conditions. CYP2D6 is involved in the metabolism of risperidone to 9-hydroxy (OH)-risperidone. CYP2C9 enzyme is also involved in the metabolism of several psychotropic drugs, although there are no data about its implication in risperidone metabolism. The present study aimed to evaluate the influence of CYP2D6 and CYP2C9 genotypes, and plasma concentrations of risperidone and 9-OH-risperidone on the QTc interval in patients under steady-state conditions. The relevance of CYP2D6 and CYP2C9 genotypes on risperidone metabolism was also analysed. Thirty-five White European psychiatric patients receiving risperidone monotherapy were studied. QTc interval was longer (p <0.05) in subjects with one active CYP2D6 gene compared to those with two. The number of CYP2D6 active genes was related to the dose-corrected plasma concentration of risperidone (p <0.05), the active moiety (risperidone plus 9-OH-risperidone) (p <0.05) and the risperidone/9-OH-risperidone ratio (p <0.05). CYP2C9 genotypes were not related to plasma concentrations of risperidone or 9-OH-risperidone, nor QTc interval. The results suggest that CYP2D6, but not CYP2C9, may be related to QTc lengthening during treatment with risperidone. The effect of the CYP2D6 genotype in risperidone metabolism is also shown.

KW - 9-hydroxy-risperidone

KW - CYP2C9

KW - CYP2D6

KW - QTc

KW - Risperidone

UR - http://www.scopus.com/inward/record.url?scp=3242732096&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3242732096&partnerID=8YFLogxK

U2 - 10.1177/0269881104042618

DO - 10.1177/0269881104042618

M3 - Article

VL - 18

SP - 189

EP - 193

JO - Journal of Psychopharmacology

JF - Journal of Psychopharmacology

SN - 0269-8811

IS - 2

ER -